Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Nalbuphine Allergy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 240 Neoplasms 179 Prostatic Neoplasms 107 Polycystic Ovary Syndrome 104 Colorectal Neoplasms 97 Carcinoma, Hepatocellular 93 Carcinoma, Non-Small-Cell Lung 81 Lung Neoplasms 60 Stomach Neoplasms 57 Precursor Cell Lymphoblastic Leukemia-Lymphoma 55 Pain 54 Neoplasm Metastasis 47 Multiple Myeloma 45 Pancreatic Neoplasms 43 Keratosis, Actinic 42 Pain, Postoperative 40 Leukemia, Myeloid, Acute 38 Leiomyoma 37 Head and Neck Neoplasms 36 Recurrence 35 Liver Neoplasms 35 Lymphoma 33 Uterine Cervical Neoplasms 32 Colonic Neoplasms 32 Brain Neoplasms 32 Papillomavirus Infections 31 Infertility 30 Lymphoma, Follicular 28 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 28 Leukemia 28

Interventions

Nalbuphine 1 Morphine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05073744 2022-12-29

Nalbuphine Versus Morphine for Perioperative Tumor Ablation

Zhongda Hospital

Phase 4 Unknown

Nalbuphine Allergy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡